Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus.

doi:10.1016/s0021-9258(18)54668-8

Paper

Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus.

Published Nov 15, 1991 · J. Balzarini, Chong-kyo Lee, P. Herdewijn

The Journal of biological chemistry

Q1 SJR score

96

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Highly Cited

Study Snapshot

Ribavirin enhances the anti-HIV activity of 2',3'-dideoxyinosine by increasing IMP levels and stimulating the conversion of ddIno to its antivirally active metabolite ddATP, while guanosine and 2'-deoxygua

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus.

References

Citations

Inhibitors of Nucleotide Biosynthesis as Candidates for a Wide Spectrum of Antiviral Chemotherapy

Inhibitors of pyrimidine and purine nucleotide biosynthesis show potential as a broad spectrum of antiviral chemotherapy against current and future pathogenic viruses.

Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines

Drug-induced liver injury (DILI) is underrecognized and underrecognized, with a higher incidence in Asia due to tuberculosis treatment and the widespread use of traditional and complementary medicines.

Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients.

Abacavir does not significantly alter ribavirin or ribavirin triphosphate concentrations in hepatitis C virus-infected patients.

Synthesis of carbocyclic nucleoside analogs with five-membered heterocyclic nucleobases.

The pyrazole amide 15f shows modest anti-HIV-1 activity, suggesting potential as a new anti-HIV and anti-HCV agent.

Management of acute and chronic HCV infection in persons with HIV coinfection.

Oral HCV direct-acting antiviral combination therapies show promise for effectively managing acute and chronic HCV infection in HIV-infected individuals, with HIV coinfection not impairing HCV cure.

Hepatotoxicity and drug interactions in liver transplant candidates and recipients.

Drug-induced liver injury is not generally higher in patients with cirrhosis, but tuberculosis medications and HIV medications can cause significant interactions, but with careful monitoring, these interactions can be effectively managed.

Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis.

Recent advances in viral mutagens and the Vif-APOBEC interaction show promise for targeting viral mutation rates and potentially improving clinical translation.

Exploiting the Anti-HIV-1 Activity of Acyclovir: Suppression of Primary and Drug-Resistant HIV Isolates and Potentiation of the Activity by Ribavirin

Acyclovir effectively suppresses primary and drug-resistant HIV-1 in human tissues, with ribavirin further enhancing this effect.